

A Systematic Review and Meta-Analysis of Digital Application use in Clinical Research in Pain Medicine

1 Ashish Shetty^{2**}, Gayathri Delanerolle^{1**}, Yutian Zeng^{8,9***}, Jian Qing Shi^{8,9****}, Rawan
2 Ebrahim³, Joanna Pang⁴, Dharani Hapangama⁶, Martin Sillem¹³, Suchith Shetty¹⁸,
3 Balakrishnan Shetty¹⁵, Martin Hirsch^{10,3}, Vanessa Raymont¹⁷, Kingshuk Majumder⁷, Sam
4 Chong^{2,3}, William Goodison², Rebecca O'Hara¹¹, Louise Hull¹¹, Nicola Pluchino¹², Naresh
5 Shetty¹⁴, Sohier Elneil^{2,3****}, Tacson Fernandez^{3,16}, *Peter Phiri^{4,5****}, Robert
6 Brownstone^{2,3****}

7 ¹University of Oxford, Oxford, UK

8 ²University College London Hospitals NHS Foundation Trust, London, UK

9 ³University College London, London, UK

10 ⁴Southern Health NHS Foundation Trust, Southampton, UK

11 ⁵University of Southampton, Primary Care, Population Sciences and Medical Education Division,
12 Southampton, UK

13 ⁶Liverpool Women's NHS Foundation, Liverpool, UK

14 ⁷University of Manchester NHS Foundation Trust, Manchester, UK

15 ⁸Southern University of Science and Technology, Shenzhen, China

16 ⁹Alan Turing Institute, London, UK

17 ¹⁰Oxford University Hospitals NHS Foundation Trust, Oxford, UK

18 ¹¹Robinson Research Institute, University of Adelaide, Adelaide, Australia

19 ¹²University of Geneva, Geneva, Switzerland

20 ¹³Praxisklinik am Rosengarten Mannheim, Saarland University Medical Centre, Homburg, Germany

21 ¹⁴M.S. Ramaiah Medical College, Bangalore, India

22 ¹⁵Sri Siddhartha University, Tumkur, India

23 ¹⁶Royal National Orthopaedic Hospital, London, UK

24 ¹⁷Department of Psychiatry, University of Oxford, Oxford, UK

25 ¹⁸Eötvös Loránd University, Budapest, Hungary

26 **These authors share first authorship

27 ***These authors share second authorship

28 ****These authors share last authorship

29 * **Correspondence:**

30 Dr Peter Phiri

31 Peter.Phiri@southernhealth.nhs.uk

32 This submission is formatted in British English.

33

34 **Keywords: chronic pain, pain management, digital app, digital medicine, mHealth**

35

36

37 **Abstract**

38 *Importance*

39 Pain is a silent global epidemic impacting approximately a third of the population. Pharmacological
40 and surgical interventions are primary modes of treatment. Cognitive/behavioural management
41 approaches and interventional pain management strategies are approaches that have been used to
42 assist with the management of chronic pain. Accurate data collection and reporting treatment
43 outcomes are vital to addressing the challenges faced. In light of this, we conducted a systematic
44 evaluation of the current digital application landscape within chronic pain medicine.

45 *Objective*

46 The primary objective was to consider the prevalence of digital application usage for chronic pain
47 management. These digital applications included mobile apps, web apps, and chatbots.

48 *Data Sources*

49 We conducted searches on PubMed and ScienceDirect for studies that were published between 1st
50 January 1990 and 1st January 2021.

51 *Study Selection*

52 Our review included studies that involved the use of digital applications for chronic pain conditions.
53 There were no restrictions on the country in which the study was conducted. Only studies that were
54 peer-reviewed and published in English were included. Four reviewers had assessed the eligibility of
55 each study against the inclusion/exclusion criteria. Out of the 84 studies that were initially identified,
56 38 were included in the systematic review.

57 *Data Extraction and Synthesis*

58 The AMSTAR guidelines were used to assess data quality. This assessment was carried out by 3
59 reviewers. The data were pooled using a random-effects model.

60 *Main Outcome(s) and Measure(s)*

61 Before data collection began, the primary outcome was to report on the prevalence of digital
62 application usage for chronic pain conditions. We also recorded the type of digital application studied
63 (e.g. mobile application, web application) and, where the data was available, the prevalence of pain
64 intensity, pain inferences, depression, anxiety, and fatigue.

65 *Results*

66 38 studies were included in the systematic review and 22 studies were included in the meta-analysis.

67 The digital interventions were categorised to web and mobile applications and chatbots, with pooled
68 prevalence of 0.22 (95% CI -0.16, 0.60), 0.30 (95% CI 0.00, 0.60) and -0.02 (95% CI -0.47, 0.42)
69 respectively. Pooled standard mean differences for symptomatology of pain intensity, depression,
70 and anxiety symptoms were 0.25 (95% CI 0.03, 0.46), 0.30 (95% CI 0.17, 0.43) and 0.37 (95% CI
71 0.05, 0.69) respectively.

72 A sub-group analysis was conducted on pain intensity due to the heterogeneity of the results
73 ($I^2=82.86\%$; $p=0.02$). After stratifying by country, we found that digital applications were more
74 likely to be effective in some countries (e.g. USA, China) than others (e.g. Ireland, Norway).

75

76 *Conclusions and Relevance*

77 The use of digital applications in improving pain-related symptoms shows promise, but further
78 clinical studies would be needed to develop more robust applications.

79

80 **Introduction**

81 High-quality research data generated by scientifically robust study designs, improved use of clinical
82 data, and the development of cost-effective healthcare models can change how medicine is practiced
83 in the modern world. Digital medicine (DM), wherein multimodal and multidimensional digital tools
84 are used to intervene in accessing and providing healthcare, is now a fundamental part of these
85 drivers of change.

86 Despite relative growth profoundly impacting gross economic improvement, ‘*bench to bedside*’
87 pathways still take considerable time (). Equally robust research evaluations have not kept pace with
88 a growing global population, although, the intellectual and healthcare evolution has modernised
89 clinical practice by way of clinical research. Existing clinical evidence and incorporation of
90 information technology has led to more prominent use of DM. A fundamental aspect of DM is to
91 improve and promote evidence-based medicine (EBM) and/or evidence-based practices (EBP) within
92 clinical and healthcare frameworks, underpinned by data science and technologies.

93 The field of pain medicine in adults is a particularly challenging area of clinical practice for many
94 reasons, including subjectivity associated with patient-reported outcomes and management of
95 symptomatology with limited information on pathophysiology (). Considering this uncertainty,
96 attempts by clinicians to categorise pain and decide on treatment interventions (Supplementary Table
97 1), could benefit from the concepts of DM and its associates of EBM and EBP. Pain is often the
98 commonest symptom that patients present with in outpatient clinics. The need for individualised care
99 based on generalisable research is complicated by wide variables, subjective nature, and inherent bias
100 which provide a unique set of challenges for a simple protocol to work. The use of cognitive
101 technology such as artificial intelligence, in delivering personalised care, based on available
102 evidence, is therefore an attractive proposition for pain medicine.

103 [SUPPLEMENTARY TABLE 1]

104 Pain medicine has been identified as a specialty that would vastly benefit from the personalisation of
105 care.¹ A current example of this need is the variable efficacy of pharmacotherapy in relieving chronic
106 pain. Opioids, for instance, have been routinely used to treat chronic pain syndromes, despite only
107 modest evidence for their use.² This has the potential for significant harm in patients where it has
108 been used inappropriately and may have influenced factors that led to the Opioid Crisis globally,
109 especially so in the USA and UK. Traditional pain evaluation methods are vulnerable to recall error
110 and bias as they rely on retrospective reporting of pain variations.³ Pain perception combined with
111 measuring functional changes and physiological parameters affected by pain are important secondary
112 outcome data to assess efficacy. Methods demanding frequent, repeated pain evaluation and pain-
113 associated features are required to formulate chronic pain management strategies.^{4,5} This approach
114 was previously hindered both by the resources required for such vast data collection, and the
115 complexity of the statistical analysis required to interpret the resulting datasets.⁶

116

117 To advance DM concepts and their use in pain medicine research, it is imperative to assess the global
118 regulatory sphere. Over the last decade, a plethora of legislations and regulatory guidelines around
119 DM have been developed by the World Health Organisation (WHO),⁷ Medicines and Healthcare
120 products Regulatory Agency (MHRA),⁸ Food and Drug Administration (FDA)⁹ and National
121 Institute for Health and Care Excellence (NICE)¹⁰ (Supplementary Table 2). However, there are
122 complexities around evaluating Artificial Intelligence (AI)-based applications that fall under the
123 category of DM. This includes those using algorithms based on machine learning (ML) models that
124 may be categorised as a medical device. Furthermore, development of AI applications requires
125 documentary evidence that the planning, designing, and development phases meet the globally
126 accepted International Organisation for Standardisation (ISO) standards. In order to achieve ISO
127 standards, a high proficiency of conformances should be maintained by the research group
128 responsible for developing the intervention that could be mass produced. As part of this
129 standardisation process, the intervention may undergo several non-conformity assessments as well as
130 vigorous testing and validation prior to being deployed.

131 [SUPPLEMENTARY TABLE 2]

132 The regulatory and standards required for novel innovations are also dependent on the disease
133 classification. The current classification of chronic and acute pain conditions (Figure 1 and Figure 2
134 respectively) employs the guidelines published by the International Association for the Study of Pain.
135 Clinicians evaluating both chronic and acute chronic pain are considering changes to guidelines to
136 provide better diagnoses and improve outcomes for patients. Advancements in the understanding of
137 the pathophysiology of acute and chronic pain have resulted in effective pharmacological approaches
138 to sub-populations of patients.

139 [FIGURE 1]

140 [FIGURE 2]

141 A critical step of DM is the development of digital tools using large sets of datasets and aggregated
142 data to create novel paradigms of care. This is also referred to as evidence-based digital medicine
143 which uses EBM concepts. To disperse these paradigms, computer programming, utility and broad
144 access of applications are vital. The development of smartphone applications is key to deliver the
145 DM phenomenon to facilitate communication and engagement between clinicians and patients. A key
146 element would be to personalise both treatments and applications using sensors and programming
147 capabilities that would support significant benefits as summarised in Supplementary Table 3.

148 [SUPPLEMENTARY TABLE 3]

149 Evaluating the current DM landscape is equally important as developing novel applications. The
150 accessibility of smartphones has given rise to multiple pilots of app-based longitudinal assessment
151 programmes for chronic pain, which have shown promising early results.^{11,12} Furthermore, the use of
152 validated lifestyle devices such as the FitBit® as monitoring adjuncts could be combined with
153 questionnaires and activity programmes to allow regular functional reassessment among chronic pain
154 patients.¹³

155 Therefore, the primary aims of this study were to: (1) identify and report the current prevalence of
156 DM application in pain medicine ; (2) identify and report the current DM application use within pain
157 medicine. To achieve this, we aimed to explore the prevalence of these types of assessments' use and
158 deployment of these using DM applications.

159 **Materials and methods**

160 An evidence synthesis methodology was developed for the purpose of this study, with a systematic
161 review protocol published on PROSPERO (CRD42021248232). The Preferred Reporting Items for
162 Systematic Reviews and Meta-analyses (PRISMA) was used to report findings.

163 *Search strategy and study selection*

164 PubMed and ScienceDirect were used to identify relevant studies that were peer-reviewed and
165 published in English between the 1st of January 1990 and 1st of January 2021. Search terms used
166 included *Chronic Pain, Pain Clinical Trials, Pain medicine, Pain medicine clinical research* and
167 *Digital Clinical Trials*. All studies using DM applications for chronic pain conditions were included.
168 Only studies that were peer-reviewed and published in English were included. Suitable publications
169 were selected using the PICO (Population/Participants, Intervention(s), Comparison, Outcome)
170 strategy. An independent reviewer screened studies included within the study by reading the full text.
171 Initial title and abstracts for identified articles were screened by 4 investigators. Inclusion and
172 exclusion criteria were assessed against each study. This was followed with the screening of the full
173 study article independently by 2 investigators and included into the final data pool.

174 *Data extraction and synthesis*

175 The data extraction process involved reading titles and abstracts followed by the application of the
176 refinement protocol where the full text was reviewed and subsequently verified. Key study details
177 such as study title, citation details, methods, findings, limitations, characteristics of the study and
178 conclusions were extracted. Differing opinions were resolved by review and discussion between the
179 lead authors. The authors remained unblinded regarding the publisher details. A full methodological
180 description is demonstrated within the supplementary document (Figure 3).

181 [FIGURE 3]

182 *Data analysis*

183 As all studies reported the mean and SD at several time points, a mathematical model was formulated
184 as demonstrated in Supplementary Figure 1.

185 [SUPPLEMENTARY FIGURE 1]

186 BPI, NRS, PCP-S and pain evaluation questionnaires were used to assess pain intensity and pain
187 interference; HADS, CES-D, BDI, PHQ-9, DASS, GAD-7 and STAI were used to assess depression
188 and anxiety; FSS and MOS sleep scale were used to assess fatigue and sleep. All studies reported the
189 mean and SD of the questionnaires across several timepoints, at baseline and follow-up. The baseline
190 questionnaire score was subtracted from the follow-up questionnaire score to standardize the data and
191 remove the initial effect. Score changes between these two time points reflect the treatment effect.
192 $(x_e^0 - x_e^1)$ represented the change in the questionnaire scores between baseline (⁰) and follow-up (¹)
193 in the treatment group, which also indicated an improvement of treatments, and $(x_c^0 - x_c^1)$
194 represented the change in the questionnaire scores between baseline (⁰) and follow-up (¹) in the
195 control group.

196 Therefore, $(x_e^0 - x_e^1) - (x_c^0 - x_c^1)$ showed the mean difference (MD) of the change of score between
197 the two groups, which is the outcome of focus. If $(x_e^0 - x_e^1) - (x_c^0 - x_c^1)$ is positive, it indicates the
198 treatment was beneficial for patients in improving symptoms of pain. However, if $(x_e^0 - x_e^1) -$
199 $(x_c^0 - x_c^1)$ is negative, it indicates the treatment had no effect on improving pain.

200 $MD = (x_e^0 - x_e^1) - (x_c^0 - x_c^1)$

201 $MD \sim \mathcal{N} \left((m_e^0 - m_e^1) - (m_c^0 - m_c^1), \frac{s_e^0^2}{n_e^0} + \frac{s_e^1^2}{n_e^1} + \frac{s_c^0^2}{n_c^0} + \frac{s_c^1^2}{n_c^1} \right)$

202 The scales of the questionnaires were different, therefore standardized mean differences (SMD) were
 203 used to illustrate the change in the mean score of the treatment group versus the control group from
 204 baseline to follow-up. The traditional form of SMD was

$$\widehat{g}_k = \left(1 - \frac{3}{4n_k - 9}\right) \frac{\widehat{u}_{ek} - \widehat{u}_{ck}}{\sqrt{((n_{ek} - 1)s_{ek}^2 + (n_{ck} - 1)s_{ck}^2)/(n_k - 2)}}$$

205 $\widehat{Var}(\widehat{g}_k) = \frac{n_k}{n_{ek} \cdot n_{ck}} + \frac{\widehat{g}_k^2}{2(n_k - 3.94)}$

206 where $n_k = n_{ek} + n_{ck}$, n_{ek} , \widehat{u}_{ek} , s_{ek} are the number, mean and standard variation of treatment
 207 group. n_{ck} , \widehat{u}_{ck} , s_{ck} are the number, mean and standard variation of the control group. The 95%
 208 confidence interval (CI) was obtained by

209 $\widehat{g}_k \pm 1.96 * S.E.(\widehat{g}_k)$

210 where $S.E.(\widehat{g}_k) = \sqrt{\widehat{Var}(\widehat{g}_k)}$.

211 \widehat{g}_k was transformed according to the traditional form, and \widehat{g}_k and $S.E.(\widehat{g}_k)$ were calculated for each
 212 study, with a random effect model used to pool the estimators. Funnel plot graphs demonstrated the
 213 publication bias. Subgroup analysis and I^2 were used to explain heterogeneity and Egger's test was
 214 used to detect publication bias. All procedures were finished with STATA 16.1.

215 *Risk of bias*

216 The risk of bias (RoB) table (below) has been used to demonstrate the risk of bias within the
 217 randomised controlled trials used in the systematic review and meta-analysis. The RoB is reflective
 218 of a fixed set of biases within domains of study design, conduct and reporting. This combined with
 219 the quality check allows the findings of the study to be scientifically justified, and clinically viable.

220 [TABLE 3]

221 AMSTAR was used also to assess methodological quality, where the total scores range from 0-11
 222 (see Figure 4, below). An article would be considered as good quality with a score of 8-11, moderate
 223 4-7 and low 0-3.

224 [FIGURE 4]

225 *Outcomes*

226 Outcomes of this study were reported via the meta-analysis which was based on the availability of
 227 statistics reported by the systematically included studies. The following are the outcomes of this
 228 study:

- 229 - Prevalence of DM applications, including categories
- 230 - Prevalence of chronic pain conditions using DM applications for self-reporting purposes
- 231 - Prevalence of pain outcomes of depression, anxiety, pain inferences, and fatigue and sleep
- 232 problems
- 233 - Clinical significance of the prevalence data
- 234 - Research significance of the prevalence data
- 235 - Critical interpretation of the identified data
- 236 - Common themes identified within the prevalence data

237

238 **Results**

239 The search yielded 84 publications, with 38^{11,16-52} included as part of the systematic review (Table 1).
240 Of the 38 studies, 7 were cross-sectional and lacked a control group. Eight studies comprised of a
241 control and treatment group, although they either lacked statistical information completely or
242 inconsistencies were identified that were associated with the mean and SD at baseline and beta
243 coefficients at follow-up timepoints. Therefore, 16^{25,28,29,31,33,35-40,43,46,50-52} were excluded and 22<sup>11,16-
244 24,26,27,30,32,34,41,42,44,45,47-49</sup> were included into the final meta-analysis (Table 2).

245 [TABLE 1]

246 [TABLE 2]

247 *Meta-analysis*

248 All 22 studies included in the meta-analysis reported more than one pain-related symptom. One
249 primary outcome reported in 15 studies was pain intensity. 11 reported depressive symptoms and 9
250 anxiety symptoms. Pain interference was reported by 4 studies. Fatigue and sleep problems were
251 included as secondary outcomes in two and one study respectively. Meta-analyses were conducted
252 for each outcome separately.

253 [FIGURE 5a]

254 *Pain intensity*

255 All 15 studies provided the mean and SD. Therefore, the meta-analysis was based on the mean and
256 SD. Figure 6 demonstrates a pooled SMD of 0.25 with a 95%CI of 0.03-0.46. SMD is statistically
257 higher than 0; therefore, pain scores within the treatment group reduced compared to the control
258 group, suggesting DM applications can significantly reduce symptoms of pain. A high heterogeneity
259 of $I^2=82.86\%$ was identified for this group ($p=0.02$). A subgroup analysis was conducted to analyse
260 the possible source of heterogeneity.

261 [FIGURE 5b]

262 *Depression*

263 The 11 studies reporting depressive symptoms used various assessment tools, including the Centre
264 for Epidemiological Studies-Depression (CES-D), Beck Depression Inventory (BDI), Patient Health
265 Questionnaire-8 and -9 (PHQ-8, PHQ-9), Hospital Anxiety and Depression Scale (HADS) and the
266 Depression Anxiety Stress Scales (DASS). Ruehlman and colleagues (2012) used CES-D and DASS

267 to assess the depression of the participants twice. To avoid duplication we used only one (CES-D) of
268 the means and SD of these two assessments so that 11 studies were included in meta-analysis. Figure
269 7 showed that the pooled SMD was 0.30 with a 95%CI of 0.17-0.43, suggesting the use of DM
270 applications reduced depression symptoms compared with the usual standard care, with an elevated
271 heterogeneity of $I^2 = 34.72\%$ ($p=0.00$).

272 [FIGURE 5c]

273 *Anxiety*

274 Within the 9 studies reporting anxiety as a clinical outcome among chronic pain participants, the
275 pooled SMD was 0.37 with a 95%CI of 0.05-0.69 (Figure 8). The SMD is significantly greater than
276 0, indicating anxiety symptoms among participants following use of DM applications improved more
277 than the control group. Additionally, a treatment effect greater than 0 was seen in each individual
278 study, thus each study concluded that DM applications improve anxiety symptoms compared with
279 controls. Heterogeneity seen within this dataset was high with $I^2 = 88.34\%$ ($p=0.02$), indicating a
280 significant effect of the DM applications compared with the control group.

281 [FIGURE 6a]

282 *Pain interference*

283 Four studies reported pain interference, an important outcome in pain research. Figure 6a
284 demonstrates a pooled SMD of 0.15 with a 95%CI of -0.05–0.34. SMD was not significantly higher
285 than 0, suggesting that the improvement within the treatment group was not significantly greater than
286 control group. DM applications appear to have no effect on participants exposed to the application
287 based on an $I^2 = 12.5\%$, indicating mild heterogeneity. Therefore, a lack of a statistically obvious effect has
288 been observed within the pooled dataset.

289 *Fatigue/sleep*

290 Two studies reported on fatigue and one study on sleep issues. The forest plots for these factors are
291 illustrated below (Figures 6b and 6c).

292 [FIGURE 6b]

293 [FIGURE 6c]

294 The pooled SMD for fatigue was 0.29, indicating the treatment group improved following the
295 completion of the DM application use. However, this conclusion is not statistically significant given
296 the 95%CI of -0.18-0.76. This could be due to the presence of only 2 studies, and more is needed to
297 reach a conclusion.

298 The pooled SMD for sleep issues was -0.04 with a 95%CI of -0.4-0.32. This indicates that DM
299 applications did not improve sleep-related issues and is of a lower score compared to the control
300 group. However, to provide a more comprehensive conclusion to this phenomenon, further studies
301 would be required.

302

303 *Subgroup analysis*

304 Subgroup analysis was conducted to identify the source of raised heterogeneity when considering
305 studies reporting on pain intensity. Initial analysis considered the categories of DM applications
306 which included web-applications, mobile apps and chatbots. The analysis is demonstrated in Figure
307 7.

308 [FIGURE 7]

309 The pooled SMD for web-applications was 0.22, indicating web-applications could reduce the
310 intensity of pain compared to the control group. The pooled SMD of mobile apps was 0.30. This
311 demonstrates a larger effect size in relieving the intensity of pain compared to control groups and to
312 those using web-applications. The pooled SMD for chatbots was -0.02, indicating chatbots have a
313 limited effect in reducing the intensity of pain in patients compared to the controls. Heterogeneity
314 remained high in all three subgroups, so a second subgroup analysis was conducted based on
315 exposure of pain symptoms. The pain exposure sub-group analysis included identified specific pain
316 conditions: fibromyalgia, back pain, chronic pain, osteoarthritis pain, menstrual pain, and cancer-
317 related pain (Figure 8).

318 [FIGURE 8]

319 Heterogeneity could only be calculated in three of the subgroups. It remained high within these
320 pooled subgroups, although at a lower level compared to previous analyses. Cancer-related pain
321 reported the highest level of heterogeneity ($I^2=92.23\%$). Chronic pain and osteoarthritis pain groups
322 reported an I^2 of 82.44% and 85.19% respectively. However, due to the limited number of studies,
323 pain and digital application exposures, the effect size could not be comprehensively assessed. A third
324 subgroup analysis was conducted based on geographical locations (Figure 9a and 9b).

325 [FIGURE 9a]

326 [FIGURE 9b]

327 A sub-group analysis by country found that DM applications appear to be effective within
328 populations in America, China, Germany, and Netherlands, while for Ireland and Norway, a
329 statistically significant effect was lacking. Only mild heterogeneity levels were indicated for America
330 ($I^2=61.54\%$) and Germany ($I^2=45.91\%$). The heterogeneity may well be due to nationality and
331 ethnicity.

332 *Sensitivity analysis*

333 Based on the meta-analysis and the sub-group analysis conducted to demonstrate pain intensity
334 outcomes from the digital tools reported by Anderson et al,⁴⁹ Chiauuzi et al⁴² and Sun et al,³⁴ the
335 standard mean deviation (SMD) was high. The primary populations of Chiauuzi and colleagues
336 (2010) and Anderson and colleagues (2004) were African American followed by Hispanic, whilst
337 Sun et al (2017) reported on a population of Chinese patients. Similar ethnicity and race patterns
338 were found among 12 of the 15 studies in the meta-analysis. Of these, 5 reported ethnicity, although
339 over 50% of the sample size was Caucasian. The other 7 did not provide specific percentages of the
340 Caucasian representation. A sensitivity analysis was conducted to assess ethnic variability within the
341 pooled sample size, which resulted in a SMD of 0.14 with a 95%CI of -0.07-0.35 (Figure 10).

342 [FIGURE 10]

343 The sensitivity analysis reveals DM applications appear to benefit patients. However, to conclusively
344 demonstrate a statistical significance more studies would be required. The p -value where the reported
345 SMD was greater than 0 was 0.2, indicating there is a 90% probability that the DM application would
346 have a positive impact on the patient's pain. It is equally vital to recognize that the predominantly
347 African American and Hispanic population-based studies reported a SMD of 0.76 with a 95% of
348 0.48-1.05, and a study consisting entirely of African American and Hispanic participants reported a
349 SMD of 0.19 (95%CI -0.21-0.59). Sun et al (2017) reported a SMD of 1.34 with a 95% CI of 0.72-
350 1.96. Therefore, DM applications appear to have a positive impact on patients.

351 The sensitivity analysis shown in Figure 16 demonstrates strong heterogeneity. The main source of
352 heterogeneity could be the difference in the treatment interventions deployed by way of the DM
353 application. As this is associated with the interventions themselves rather than the DM applications, it
354 is beyond the scope of this study, and could be explored in the future. Pooled SMD of web-
355 application, mobile apps and chatbots were 0.22, 0.1 and -0.02 respectively. Figure 11 demonstrates
356 that the most effective DM application could be mobile apps since web-applications are not a self-
357 reported method.

358 [FIGURE 11]

359 *Publication bias*

360 Publication bias was assessed and reported using funnel plots and Egger's test to examine the small-
361 study effect. Publication bias appears to be smaller among studies associated with fatigue and sleep,
362 and higher in studies demonstrating pain intensity, depression, anxiety, and pain interferences. There
363 is a lack of significant publication bias based on the funnel plot (Figure 12a, below). The Egger's test
364 p -value is 0.932, indicating the lack of a small study effect. However, there are 5 studies that fell
365 outside the 95%CI which could affect our detection of publication bias. The p -value is not high but it
366 is limited by the data and experimental quality.

367 [FIGURE 12a]

368 [FIGURE 12b]

369 [FIGURE 12c]

370 [FIGURE 12d]

371 Figures 12b and 12c indicate a lack of publication bias statistically for depression and anxiety, with
372 Egger's test p -values of 0.838 and 0.712 respectively. Pain interferences (Figure 12d), which was
373 included in four studies, had an Egger's test p -value of 0.43, which demonstrates we cannot detect a
374 publication bias. The low numbers of studies reporting outcomes for fatigue and sleep problems
375 meant analysis of publication bias was not possible.

376

377

378

379 Discussion

380 The prevalence of DM applications within pain research appear to be moderate and is focused around
381 developed countries such as America and Germany. China appears to be the only country within Asia
382 to have conducted a study to assess the use of DM applications among patients with chronic pain.
383 This demonstrates an urgent need to conduct evaluations of these DM applications in low-income
384 and middle-income countries to optimise and evaluate the efficacy and acceptability among patients
385 and clinicians. Patient-reported DM applications identified in the systematic review could be
386 categorised primarily as mobile apps and chatbots, as EHR systems were used to assess pain-
387 associated outcomes. As a result of these differences, the prevalence of DM applications was meta-
388 analysed at a granular level to identify and report pain outcomes such as depression, anxiety, pain
389 intensity and pain inference that were assessed by the tools. The lack of uniformity among the
390 assessments used within the applications are another issue that requires further elaboration if these
391 are to be used by clinicians as part of a patient's ongoing clinical management. The assessments used
392 also appear to be non-specific to a particular group of patients. Often, the studies did not report on
393 underlying conditions or if the pain conditions had a clinical diagnosis. Thus, it is challenging to
394 demonstrate that users demonstrated true clinical benefit. This suggests there is little quantifiable data
395 to provide a comprehensive conclusion in terms of the generalisability and feasibility of these
396 applications globally.

397 We identified multiple themes and sub-themes in this analysis that were pooled as mobile
398 applications, EHR and chatbots. Mobile applications have grown rapidly to support the management
399 of pain disorders such as migraine, back pain and fibromyalgia by offering educational components,
400 exercise platforms, relaxation techniques and mindfulness-based options to name a few. These
401 options provide feedback and allow engagement and adherence of the users. This may explain why
402 mobile applications demonstrated better results compared with other DM applications in the
403 management of chronic pain. Another facet to consider is the inclusion of these datasets to maintain a
404 structured approach to deliver effective continuity of care provision. Trials promoting the evaluation
405 of data in a comprehensive manner through systems that allow the standardisation and acceptance of
406 quality data would increase the acceptance of digitised data. Trials involving DM applications that
407 incorporate AI-based clinical algorithms to assist with the evaluation of pain and outcomes in
408 patients with cancer appear encouraging.⁵³

409 Ledel Solem and colleagues (2019) reported adult participants were in favour of using DM-based
410 self-management interventions for chronic pain management.⁵⁴ Patients felt that the accessibility,
411 usability, and personalisation were vital for DM tools, and suggested that these should be further
412 developed to distract them from pain, regardless of pain intensity and cognitive capacity.

413 The benefits of harnessing DM within the context of pain medicine could improve both clinical and
414 patient-reported outcomes. Evidence-gathering to support therapeutic efficacy for pharmacological or
415 surgical treatments requires effective and robust methodology, yet rigid traditional trial designs
416 remain inefficient and struggle with implementation into clinical practice, limiting sustainability
417 within healthcare systems. Computer-based technology could address these obstacles in research. The
418 flexibility and accessibility of digital technology enables a more convenient and improved consenting
419 process. This could allow easier enrolment and participation in studies for populations disadvantaged
420 by mobility or literacy issues. Increased recruitment and retention lead to larger study populations
421 with greater data validity, and aids researchers by speeding up recruitment and assessment of large
422 trial populations.

423 Digital clinical trials are key in collating all the above factors, as it is a fundamental tool in assessing
424 the efficacy and safety of novel drugs, medical devices, and health system interventions. Traditional
425 clinical trials have demonstrated the validity, acceptability, and sustainability of the interventions,
426 whilst digital clinical trials could leverage technologies to engage and report trial-specific
427 measurements associated with the interventions being tested at a lower cost.⁵⁹ Conceptualising digital
428 clinical trials for pain medicine could have added benefits, especially for patients who could report
429 pain episodes daily. That would allow digital analytics to assess considerations clinicians need to
430 make when developing clinical treatments. Additionally, data science approaches could be leveraged
431 in this instance to develop novel clinical methods to best utilise trial data with ‘real-world’ data to
432 develop aggregated datasets. These could be used to promote multi-morbid clinical research, which is
433 vital in furthering clinical practices associated with pain medicine.

434 *Limitations*

435 Unified approaches of conducting DM application assessments were lacking across all 3 categories
436 identified and reported within the scope of this study. As a result, the pooled analysis conducted
437 limits the generalizability of the findings. It is evident that the lack of validation in digital
438 applications is another rate-limiting factor in furthering the use of these among clinical populations.

439 *Conclusion*

440 The pain medicine ecosystem has a plethora of research studies, although those in population
441 research, prevention, clinical trials, and education, as well as training, need to evolve if
442 improvements are to be made clinically. This could integrate evolving DM concepts, including AI
443 applications, that could improve patient-reported outcomes. It is, therefore, important to conduct
444 further well-designed digital clinical trials.

445 Another concern based on evidence ascertained in this study is the minimal use of clinical trials to
446 test DM applications; therefore, the efficacy and efficiency of these, as well as the generalizability to
447 a wider population, remain limited. Pragmatic and novel methods of conducting clinical trials would
448 be beneficial in providing credible evidence before these DM applications are used within clinical
449 practice. Alternatives such as simulation studies using *real-world* environments could be used to test
450 novel DM applications, given the complexities around conducting pain research. Similarly, it may be
451 beneficial for patients to gain access to DM applications more quickly, especially those managing
452 chronic pain. Therefore, a paradox of “*no evidence, no implementation vs. no implementation, no
453 evidence*” is a challenge to clinicians, patients, policymakers, and clinical researchers alike. Using
454 simulation methods, where possible, could provide an alternative method to overcome this paradox,
455 although there may be limitations that would need considering as it not always feasible to design
456 precise simulations or perform competency validation. The proliferation of digital technologies
457 would provide the leverage to optimise global care by way of mobile platforms, to open better
458 avenues, and to measure outcome data from wearable devices. These applications use real-world data
459 that could benefit patients and clinicians alike. Thus, the use of DM in pain medicine could promote
460 a myriad of benefits.

461

462

463

464

465

466

467 **References**

- 468 1. Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, et al. Patient
469 phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. *Pain*.
470 2016;157(9):1851-1871. doi:10.1097/j.pain.0000000000000602
- 471 2. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic
472 pain: controversies, current status, and future directions. *Exp Clin Psychopharmacol*.
473 2008;16(5):405-416. doi:10.1037/a0013628
- 474 3. Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The
475 accuracy of pain and fatigue items across different reporting periods. *Pain*. 2008;139(1):146-
476 157. doi:10.1016/j.pain.2008.03.024
- 477 4. Bolger N, Laurenceau J. *Intensive longitudinal methods: An introduction to diary and*
478 *experience sampling research*. Guilford Press; 2013.
- 479 5. Fillingim RB, Loeser JD, Baron R, Edwards RR. Assessment of Chronic Pain: Domains,
480 Methods, and Mechanisms. *J Pain*. 2016;17(9 Suppl):T10-T20.
481 doi:10.1016/j.jpain.2015.08.010
- 482 6. Mun CJ, Suk HW, Davis MC, Karoly P, Finan P, Tennen H, et al. Investigating
483 intraindividual pain variability: methods, applications, issues, and directions. *Pain*.
484 2019;160(11):2415-2429. doi:10.1097/j.pain.0000000000001626
- 485 7. World Health Organization. Monitoring and Evaluating Digital Health Interventions: a
486 practical guide to conducting research and assessment.
487 [http://apps.who.int/iris/bitstream/handle/10665/252183/9789241511766-](http://apps.who.int/iris/bitstream/handle/10665/252183/9789241511766-eng.pdf;jsessionid=9630003E91620D111417E2CE52AF8075?sequence=1)
488 [eng.pdf;jsessionid=9630003E91620D111417E2CE52AF8075?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/252183/9789241511766-eng.pdf;jsessionid=9630003E91620D111417E2CE52AF8075?sequence=1). Accessed 23
489 May, 2021.
- 490 8. Medicines & Healthcare products Regulatory Agency. Custom-made devices in Great Britain.
491 [https://www.gov.uk/government/publications/custom-made-medical-devices/custom-made-](https://www.gov.uk/government/publications/custom-made-medical-devices/custom-made-devices-in-great-britain)
492 [devices-in-great-britain](https://www.gov.uk/government/publications/custom-made-medical-devices/custom-made-devices-in-great-britain). Accessed 23 May, 2021.
- 493 9. U.S. Food and Drug Administration. Factors to Consider Regarding Benefit Risk in Medical
494 Device Product Availability, Compliance, and Enforcement Decisions: Guidance for Industry
495 and Food and Drug Administration Staff.
496 [https://www.fda.gov/files/medical%20devices/published/Factors-to-Consider-Regarding-](https://www.fda.gov/files/medical%20devices/published/Factors-to-Consider-Regarding-Benefit-Risk-in-Medical-Device-Product-Availability--Compliance--and-Enforcement-Decisions---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf)
497 [Benefit-Risk-in-Medical-Device-Product-Availability--Compliance--and-Enforcement-](https://www.fda.gov/files/medical%20devices/published/Factors-to-Consider-Regarding-Benefit-Risk-in-Medical-Device-Product-Availability--Compliance--and-Enforcement-Decisions---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf)
498 [Decisions---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf](https://www.fda.gov/files/medical%20devices/published/Factors-to-Consider-Regarding-Benefit-Risk-in-Medical-Device-Product-Availability--Compliance--and-Enforcement-Decisions---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf). Accessed
499 23 May, 2021.
- 500 10. National Institute for Health and Care Excellence. Evidence standards framework for digital
501 health technologies. [https://www.nice.org.uk/Media/Default/About/what-we-do/our-](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf)
502 [programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf).
503 Accessed 23 May, 2021.
- 504 11. Gentili C, Zetterqvist V, Rickardsson J, Holmström L, Simons LE, Wicksell RK. ACTsmart:
505 Guided Smartphone-Delivered Acceptance and Commitment Therapy for Chronic Pain-A
506 Pilot Trial. *Pain Med*. 2021;22(2):315-328. doi:10.1093/pm/pnaa360

- 507 12. Bostrøm K, Børøsund E, Varsi C, Eide H, Nordang EF, Schreurs KM, et al. Digital Self-
508 Management in Support of Patients Living With Chronic Pain: Feasibility Pilot Study. *JMIR*
509 *Form Res.* 2020;4(10):e23893. doi:10.2196/23893
- 510 13. Greenberg J, Popok PJ, Lin A, Kulich RJ, James P, Macklin EA, et al. A Mind-Body Physical
511 Activity Program for Chronic Pain With or Without a Digital Monitoring Device: Proof-of-
512 Concept Feasibility Randomized Controlled Trial. *JMIR Form Res.* 2020;4(6):e18703.
513 doi:10.2196/18703
- 514 14. Jonassaint CR, Rao N, Sciuto A, Switzer GE, De Castro L, Kato GJ, et al. Abstract
515 Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional
516 Feasibility Study. *J Med Internet Res.* 2018;20(8):e10056. doi:10.2196/10056
- 517 15. van der Heijden AA, Abramoff MD, Verbraak F, van Hecke MV, Liem A, Nijpels G.
518 Validation of automated screening for referable diabetic retinopathy with the IDx-DR device
519 in the Hoorn Diabetes Care System. *Acta Ophthalmol.* 2018;96(1):63-68.
520 doi:10.1111/aos.13613
- 521 16. Bossen D, Veenhof C, Van Beek KE, Spreuwenberg PM, Dekker J, De Bakker DH.
522 Effectiveness of a web-based physical activity intervention in patients with knee and/or hip
523 osteoarthritis: randomized controlled trial. *J Med Internet Res.* 2013;15(11):e257.
524 doi:10.2196/jmir.2662
- 525 17. Hedman-Lagerlöf M, Hedman-Lagerlöf E, Axelsson E, Ljótsson B, Engelbrektsson J,
526 Hultkrantz S, et al. Internet-Delivered Exposure Therapy for Fibromyalgia: A Randomized
527 Controlled Trial. *Clin J Pain.* 2018;34(6):532-542. doi:10.1097/AJP.0000000000000566
- 528 18. Krein SL, Kadri R, Hughes M, Kerr EA, Piette JD, Holleman R, et al. Pedometer-based
529 internet-mediated intervention for adults with chronic low back pain: randomized controlled
530 trial. *J Med Internet Res.* 2013;15(8):e181. doi:10.2196/jmir.2605
- 531 19. Rini C, Porter LS, Somers TJ, McKee DC, DeVellis RF, Smith M, et al. Automated Internet-
532 based pain coping skills training to manage osteoarthritis pain: a randomized controlled trial.
533 *Pain.* 2015;156(5):837-848. doi:10.1097/j.pain.0000000000000121
- 534 20. Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced
535 management of fibromyalgia: a randomized controlled trial. *Pain.* 2010;151(3):694-702.
536 doi:10.1016/j.pain.2010.08.034
- 537 21. Wilson M, Roll JM, Corbett C, Barbosa-Leiker C. Empowering Patients with Persistent Pain
538 Using an Internet-based Self-Management Program. *Pain Manag Nurs.* 2015;16(4):503-514.
539 doi:10.1016/j.pmn.2014.09.009
- 540 22. Raj SX, Brunelli C, Klepstad P, Kaasa S. COMBAT study - Computer based assessment and
541 treatment - A clinical trial evaluating impact of a computerized clinical decision support tool
542 on pain in cancer patients. *Scand J Pain.* 2017;17:99-106. doi:10.1016/j.sjpain.2017.07.016
- 543 23. Guillory J, Chang P, Henderson Jr CR, Shengelia R, Lama S, Warmington M, et al. Piloting a
544 Text Message-based Social Support Intervention for Patients With Chronic Pain: Establishing a
545 Feasibility and Preliminary Efficacy. *Clin J Pain.* 2015;31(6):548-556.
546 doi:10.1097/AJP.0000000000000193
- 547 24. Berman RL, Iris MA, Bode R, Drengenberg C. The effectiveness of an online mind-body
548 intervention for older adults with chronic pain. *J Pain.* 2009;10(1):68-79.
549 doi:10.1016/j.jpain.2008.07.006
- 550 25. Carpenter KM, Stoner SA, Mundt JM, Stoelb B. An online self-help CBT intervention for
551 chronic lower back pain. *Clin J Pain.* 2012;28(1):14-22. doi:10.1097/AJP.0b013e31822363db

- 552 26. Menga G, Ing S, Khan O, Dupre B, Dornelles AC, Alarakhia A, et al. Fibromyalgia: can
553 online cognitive behavioral therapy help? *Ochsner J*. 2014;14(3):343-349.
554 <http://www.ochsnerjournal.org/content/14/3/343>. Accessed 15 February, 2022.
- 555 27. O'moore KA, Newby JM, Andrews G, Hunter DJ, Bennell K, Smith J, et al. Internet
556 Cognitive-Behavioral Therapy for Depression in Older Adults with Knee Osteoarthritis: A
557 Randomized Controlled Trial. *Arthritis Care Res (Hoboken)*. 2018;70(1):61-70.
558 doi:10.1002/acr.23257
- 559 28. Minen MT, Adhikari S, Seng EK, Jinich S, Powers SW, Lipton RB. Smartphone-based
560 migraine behavioral therapy: a single-arm study with assessment of mental health predictors.
561 *NPJ Digit Med*. 2019;2:46. doi:10.1038/s41746-019-0116-y
- 562 29. Toelle TR, Utpadel-Fischler DA, Haas KK, Priebe JA. App-based multidisciplinary back pain
563 treatment versus combined physiotherapy plus online education: a randomized controlled
564 trial. *NPJ Digit Med*. 2019;2:34. doi:10.1038/s41746-019-0109-x
- 565 30. Blödt S, Pach D, Eisenhart-Rothe SV, Lotz F, Roll S, Icke K, et al. Effectiveness of app-
566 based self-acupressure for women with menstrual pain compared to usual care: a randomized
567 pragmatic trial. *Am J Obstet Gynecol*. 2018;218(2):227.e1-227.e9.
568 doi:10.1016/j.ajog.2017.11.570
- 569 31. Irvine AB, Russell H, Manocchia M, Mino DE, Glassen TC, Morgan R. Mobile-Web app to
570 self-manage low back pain: randomized controlled trial. *J Med Internet Res*.
571 2015;17(1):e3130. doi:10.2196/jmir.3130
- 572 32. Schatz J, Schlenz AM, McClellan CB, Puffer ES, Hardy S, Pfeiffer M, et al. Changes in
573 coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for
574 pediatric sickle cell disease using smartphones. *Clin J Pain*. 2015;31(6):536-547.
575 doi:10.1097/AJP.0000000000000183
- 576 33. Skrepnik N, Spitzer A, Altman R, Hoekstra J, Stewart J, Toselli R. Assessing the Impact of a
577 Novel Smartphone Application Compared With Standard Follow-Up on Mobility of Patients
578 With Knee Osteoarthritis Following Treatment With Hylan G-F 20: A Randomized
579 Controlled Trial. *JMIR Mhealth Uhealth*. 2017;5(5):e64. doi:10.2196/mhealth.7179
- 580 34. Sun Y, Jiang F, Gu JJ, Wang YK, Hua H, Li J, et al. Development and Testing of an
581 Intelligent Pain Management System (IPMS) on Mobile Phones Through a Randomized Trial
582 Among Chinese Cancer Patients: A New Approach in Cancer Pain Management. *JMIR*
583 *Mhealth Uhealth*. 2017;5(7):e108. doi:10.2196/mhealth.7178
- 584 35. Guétin S, Brun L, Deniaud M, Clerc JM, Thayer JF, Koenig J. Smartphone-based Music
585 Listening to Reduce Pain and Anxiety Before Coronarography: A Focus on Sex Differences.
586 *Altern Ther Health Med*. 2016;22(4):60-63.
- 587 36. Jamison RN, Jurcik DC, Edwards RR, Huang CC, Ross EL. A Pilot Comparison of a
588 Smartphone App With or Without 2-Way Messaging Among Chronic Pain Patients: Who
589 Benefits From a Pain App? *Clin J Pain*. 2017;33(8):676-686.
590 doi:10.1097/AJP.0000000000000455
- 591 37. Jibb LA, Stevens BJ, Nathan PC, Seto E, Cafazzo JA, Johnston DL, et al. Implementation and
592 preliminary effectiveness of a real-time pain management smartphone app for adolescents
593 with cancer: A multicenter pilot clinical study. *Pediatr Blood Cancer*. 2017;64(10):e26554.
594 doi:10.1002/pbc.26554
- 595 38. Lee M, Lee SH, Kim T, Yoo HJ, Kim SH, Suh DW. Feasibility of a Smartphone-Based
596 Exercise Program for Office Workers With Neck Pain: An Individualized Approach Using a

- 597 Self-Classification Algorithm. *Arch Phys Med Rehabil*. 2017;98(1):80-87.
598 doi:10.1016/j.apmr.2016.09.002
- 599 39. Oldenmenger WH, Witkamp FE, Bromberg JE, Jongen JL, Lieverse PJ, Huygen FJ, et al. To
600 be in pain (or not): a computer enables outpatients to inform their physician. *Ann Oncol*.
601 2016;27(9):1776-1781. doi:10.1093/annonc/mdw250
- 602 40. Huber S, Priebe JA, Baumann KM, Plidschun A, Schiessl C, Tölle TR. Treatment of Low
603 Back Pain with a Digital Multidisciplinary Pain Treatment App: Short-Term Results. *JMIR*
604 *Rehabil Assist Technol*. 2017;4(2):e11. doi:10.2196/rehab.9032
- 605 41. Calner T, Nordin C, Eriksson MK, Nyberg L, Gard G, Michaelson P. Effects of a self-guided,
606 web-based activity programme for patients with persistent musculoskeletal pain in primary
607 healthcare: A randomized controlled trial. *Eur J Pain*. 2017;21(6):1110-1120.
608 doi:10.1002/ejp.1012
- 609 42. Chiauzzi E, Pujol LA, Wood M, Bond K, Black R, Yiu E, et al. painACTION-back pain: a
610 self-management website for people with chronic back pain. *Pain Med*. 2010;11(7):1044-
611 1058. doi:j.1526-4637.2010.00879.x
- 612 43. Davis MC, Zautra AJ. An online mindfulness intervention targeting socioemotional
613 regulation in fibromyalgia: results of a randomized controlled trial. *Ann Behav Med*.
614 2013;46(3):273-284. doi:10.1007/s12160-013-9513-7
- 615 44. Dowd H, Hogan MJ, McGuire BE, Davis MC, Sarma KM, Fish RA, et al. Comparison of an
616 Online Mindfulness-based Cognitive Therapy Intervention With Online Pain Management
617 Psychoeducation: A Randomized Controlled Study. *Clin J Pain*. 2015;31(6):517-527.
618 doi:10.1097/AJP.0000000000000201
- 619 45. Lin J, Wurst R, Paganini S, Hohberg V, Kinkel S, Göhner W, et al. A group- and smartphone-
620 based psychological intervention to increase and maintain physical activity in patients with
621 musculoskeletal conditions: study protocol for a randomized controlled trial ("MoVo-App").
622 *Trials*. 2020;21(1):502. doi:10.1186/s13063-020-04438-4
- 623 46. Nordin CA, Michaelson P, Gard G, Eriksson MK. Effects of the Web Behavior Change
624 Program for Activity and Multimodal Pain Rehabilitation: Randomized Controlled Trial. *J*
625 *Med Internet Res*. 2016;18(10):e265. doi:10.2196/jmir.5634
- 626 47. Ruehlman LS, Karoly P, Enders C. A randomized controlled evaluation of an online chronic
627 pain self management program. *Pain*. 2012;153(2):319-330. doi:10.1016/j.pain.2011.10.025
- 628 48. Ström L, Pettersson R, Andersson G. A controlled trial of self-help treatment of recurrent
629 headache conducted via the Internet. *J Consult Clin Psychol*. 2000;68(4):722-727.
630 doi:10.1037/0022-006x.68.4.722
- 631 49. Anderson KO, Mendoza TR, Payne R, Valero V, Palos GR, Nazario A, et al. Pain education
632 for underserved minority cancer patients: a randomized controlled trial. *J Clin Oncol*.
633 2004;22(24):4918-4925. doi:10.1200/JCO.2004.06.115
- 634 50. Lovell MR, Forder PM, Stockler MR, Butow P, Briganti EM, Chye R, et al. A randomized
635 controlled trial of a standardized educational intervention for patients with cancer pain. *J Pain*
636 *Symptom Manage*. 2010;40(1):49-59. doi:10.1016/j.jpainsymman.2009.12.013
- 637 51. Guétin S, Brun L, Mériadec C, Camus E, Deniaud M, Thayer JF, et al. A Smartphone-Based
638 Music Intervention to Reduce Pain and Anxiety in Women before or during labor. *EuJIM*.
639 2018;21:24-26. doi:10.1016/j.eujim.2018.06.001

- 640 52. Oldenmenger WH, Baan MAG, van der Rijt CCD. Development and feasibility of a web
641 application to monitor patients' cancer-related pain. *Support Care Cancer*. 2018;26(2):635-
642 642. doi:10.1007/s00520-017-3877-3
- 643 53. Kamdar M, Centi AJ, Agboola S, Fischer N, Rinaldi S, Strand JJ, et al. A randomized
644 controlled trial of a novel artificial intelligence-based smartphone application to optimize the
645 management of cancer-related pain. *J Clin Onc*. 2019;37:11514.
646 doi:10.1200/JCO.2019.37.15_suppl.11514
- 647 54. Solem IK, Varsi C, Eide H, Kristjansdottir OB, Mirkovic J, Børøsund E, et al. Patients' Needs
648 and Requirements for eHealth Pain Management Interventions: Qualitative Study. *J Med*
649 *Internet Res*. 2019;21(4):e13205. doi:10.2196/13205
- 650 55. Witzeman K, Flores OA, Renzelli-Cain RI, Worly B, Moulder JK, Carrillo JF, et al. Patient-
651 Physician Interactions Regarding Dyspareunia with Endometriosis: Online Survey Results. *J*
652 *Pain Res*. 2020;13:1579-1589. doi:10.2147/JPR.S248887
- 653 56. McConnell MV, Shcherbina A, Pavlovic A, Homburger JR, Goldfeder RL, Waggot D, et al.
654 Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts
655 Cardiovascular Health Study. *JAMA Cardiol*. 2017;2(1):67-76.
656 doi:10.1001/jamacardio.2016.4395
- 657 57. Urteaga I, McKillop M, Elhadad N. Learning endometriosis phenotypes from patient-
658 generated data. *NPJ Digit Med*. 2020;3:88. doi:10.1038/s41746-020-0292-9
- 659 58. Jacobson NC, Summers B, Wilhelm S. Digital Biomarkers of Social Anxiety Severity: Digital
660 Phenotyping Using Passive Smartphone Sensors. *J Med Internet Res*. 2020;22(5):e16875.
661 doi:10.2196/16875
- 662 59. Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, Cooper-Arnold K, et al.
663 Digitizing clinical trials. *NPJ Digit Med*. 2020;3(101):1-7. doi:10.1038/s41746-020-0302-y
- 664 60. Guo C, Ashrafian H, Ghafur S, Fontana G, Gardner C, Prime M. Challenges for the
665 evaluation of digital health solutions-A call for innovative evidence generation approaches.
666 *NPJ Digit Med*. 2020;3:110. doi:10.1038/s41746-020-00314-2

667

668 Acknowledgments

669 This paper is part of the multifaceted ELEMI project that is sponsored by Southern Health NHS
670 Foundation Trust and in collaboration with the University of Liverpool, University College London,
671 University College London NHS Foundation Trust, Liverpool Women's Hospital, University of
672 Southampton, Robinson Institute-University of Adelaide, Ramaiah Memorial Hospital (India),
673 University of Geneva and Manchester University NHS Foundation Trust.

674 This paper is also part of the POP project focusing on Chronic Pain that is sponsored by University
675 College London NHS Foundation Trust and in collaboration with University of Oxford and
676 University of Southampton.

677 Funding

678 GD, and PP are supported by National Institute for Health Research (NIHR) Research Capability
679 Funding (RCF) and by Southern Health NHS Foundation Trust. AS is supported by industry funding.

680 Author Contributions

681 GD conceptualised the logic model of this paper and developed the systematic methodology. GD and
682 AS wrote the first draft of the manuscript. The systematic methodology was critically appraised by
683 AS and GD initially. RE, GD and AS extracted the data. This data was reviewed by GD and AS. GD,
684 JS and YZ developed the statistical analysis plan. JS, YZ, GD, TF and AS conducted the full
685 analysis. The full paper was critically appraised by all authors. All authors approved the final version
686 of the manuscript.

687 **Conflict of Interest**

688 PP has received research grant from Novo Nordisk, and other, educational from Queen Mary
689 University of London, other from John Wiley & Sons, other from Otsuka, outside the submitted
690 work. SR reports other from Janssen, 691 Lundbeck and Otsuka outside the submitted work. All
691 other authors report no conflict of interest.

692 TF has received funding from Boston Scientific. AS is the Chief Medical Officer for Nurokor
693 Medical Systems.

694 The views expressed are those of the authors and not necessarily those of the NHS, the National
695 Institute for Health Research, the Department of Health and Social Care or the Academic institutions.

696 **Data Availability Statement**

697 All data used within this study has been publicly available. The authors will consider sharing the
698 dataset gathered upon request.

699

700 **Figure legends**

701 Figure 1: Chronic Pain Classification Tree (CPCT)

702 Figure 2: Acute Pain Classification Tree

703 Figure 3: Representation of the PRISMA Flowchart

704 Figure 4: AMSTAR assessment

705 Figure 5a: Forest plot of pain intensity

706 Figure 5b: Forest plot of depression

707 Figure 5c: Forest plot for anxiety

708 Figure 6a: Forest plot for pain interference

709 Figure 6b: Forest plot of fatigue

710 Figure 6c: Forrest plot of sleep

711 Figure 7: Subgroup analysis for pain intensity (web-application, mobile apps, chatbots)

712 Figure 8: Subgroup analysis for pain intensity (by pain type)

713 Figure 9a: Subgroup analysis for pain intensity (by country)

714 Figure 9b: Geographical spread of data collected for the systematic review

715 Figure 10: Sensitivity analysis without 3 BAME studies^{31,39,58}

716 Figure 11: Sensitivity analysis without 3 BAME studies^{31,39,58} (sub-grouped by digital applications)

717 Figure 12a: Funnel plot for pain intensity & Egger's test for pain intensity

718 Figure 12b: Funnel plot for depression & Egger's test for depression

719 Figure 12c: Funnel plot for anxiety & Egger's test for anxiety

720 Figure 12d: Funnel plot for pain inferences & Egger's test for pain inferences

721

722

723 **Tables**

724 **Table 1.** Characteristics of the systematically included studies

Author	Diagnosis/Treatment method	Digital application and method of application delivery	Study type	Sample size	Country	Exposure
Bossen et al (2013)	Intervention	Web-based intervention	RCT	199	Netherlands	osteoarthritis pain
Hedman-Lagerlöf, et al (2018)	Intervention	Web-based intervention	RCT	140	Sweden	fibromyalgia
Krein et al (2013)	Intervention	Web-based intervention	RCT	229	USA	chronic low back pain
Rini et al (2015)	Intervention	Web-based intervention	RCT	113	USA	osteoarthritis pain
Williams et al (2010)	Intervention	Web-based intervention	RCT	118	USA	fibromyalgia
Wilson et al (2015)	Intervention	Web-based intervention	RCT	92	USA	chronic noncancer pain
Raj et al (2017)	Intervention	Web-based intervention	RCT	214	Norway	cancerrelated pain
Guillory et al (2015)	Chatbots	Text message and mobile app	RCT Feasibility	68	USA	chronic noncancer pain

Berman et al (2009)	Chatbots	Web-based intervention	RCT	78	USA	chronic pain
Carpenter et al (2012)	Chatbots- Cognitive behavioral therapy with chapters	Web-based intervention	RCT Pilot	141	USA	chronic low back pain
Menga et al (2014)	Chatbots- Cognitive behavioral therapy with chapters	Web-based intervention	RCT	44	USA	Fibromyalgia
O'moore et al (2018)	Chatbots- Cognitive behavioral therapy with chapters	Web-based intervention	RCT	69	USA	osteoarthritis pain
Gentili et al (2020)	Mobile app based acceptance therapy	Mobile based intervention	RCT pilot	31	Sweden	chronic pain
Minen et al (2019)	Mobile app based behavioral therapy	Mobile based intervention	Crosssectional - Feasibility	51	USA	migraine
Toelle et al (2019)	Mobile app based therapy	Mobile based intervention	RCT	94	Germany	Chronic nonspecific low back pain
Blödt et al (2018)	Mobile app based self-acupressure	Mobile based intervention	RCT - Pragmatic	221	Germany	menstrual pain
Irvine et al	Mobile app based	Mobile based	RCT	597	USA	chronic low

(2015)	self-management	intervention				back pain
Schatz et al (2015)	Mobile app based coping, pain and activity	Mobile based intervention	RCT	46	USA	chronic pain for paediatric sickle cell
Nebojsa et al (2017)	Mobile app and an wearable activity monitor	Mobile based intervention	RCT	211	USA	osteoarthritis pain
Sun et al (2017)	Mobile app for pain management	Mobile based intervention	RCT	46	China	cancer-related pain
Guétin et al (2016)	Mobile app delivering music therapy for pain	Mobile based intervention	RCT	106	France	chronic pain
Jamison et al (2017)	Mobile app based daily assessment and treatment	Mobile based intervention	RCT - pilot	90	USA	chronic pain
Jibb et al (2017)	Mobile apps	Mobile based intervention	RCT - pragmatic	40	Canada	cancer-related chronic pain among the adolescent
Lee et al (2017)	Mobile app-based exercise program	Mobile based intervention	Crosssection single group repeated measure	23	Korea	neck pain
Oldenmenger et al (2016)	Mobile apps	Web-based intervention	quantitative	48	Netherlands	cancer-related pain

Huber et al (2017)	Mobile app and EHR	Mobile based intervention	Retrospective RCT	180	Germany	chronic low back pain
Calner et al (2017)	Intervention	Web-based intervention	RCT	109	Sweden	musculoskeletal pain
Chiauzzi et al (2010)	Intervention - self-management	Web-based intervention	RCT	199	USA	chronic pain
Davis et al (2013)	Intervention of mindfulness	Web-based intervention	RCT	79	USA	fibromyalgia
Dowd et al (2015)	Online mindfulness-based cognitive therapy intervention	Web-based intervention	RCT	124	Ireland	chronic pain
Lin et al (2020)	Mobile apps	Web-based intervention	RCT	302	Germany	multimodal pain
Nordin et al (2016)	Intervention for web behaviour change	Web-based intervention	RCT	109	Sweden	Multimodal pain
Ruehlmana et al (2012)	Intervention self-management	Web-based intervention	RCT	305	USA	chronic pain
Ström et al (2000)	Intervention – self-management	Web-based intervention	RCT	45	Sweden	recurrent headache
Anderson et al (2004)	Intervention - video and booklet	Web-based intervention	RCT	97	USA	Cancer-related pain

Lovell et al (2010)	Intervention – video and booklet	Web-based intervention	RCT	217	Australia	Cancer-related pain
Guétin et al (2018)	Smartphone-based intervention	Mobile-based intervention	RCT	62	France	chronic painful conditions
Oldenmenger et al (2018)	Intervention – internet applications	Web-based intervention	cohort study	84	Netherlands	Cancer-related pain

725 *EHR = Electronic Health Records; RCT = Randomised clinical trial

726

727 **Table 2.** Studies included within the meta-analysis

Study ID	Author	Digital applications	Study type	Sample size	Country	Exposure	P-value
1	Bossen et al (2013)	web-application	RCT	199	Netherlands	osteoarthritis pain	0.33 (pain intensity); 0.09 (depression); 0.007 (anxiety)
2	Hedman-Lagerlöf et al (2018)	web-application	RCT	140	Sweden	fibromyalgia	<0.001 (depression); <0.001 (anxiety); <0.001 (fatigue)
3	Rini et al (2015)	web-application	RCT	113	USA	osteoarthritis pain	Not provided
4	Williams et al (2010)	web-application	RCT	118	USA	fibromyalgia	Not provided
5	Wilson et	web-	RCT	92	USA	chronic	0.22 (pain intensity); 0.25

	al (2015)	application				noncancer pain	(depression)
6	Raj et al (2017)	web-application	RCT	214	Norway	cancer-related pain	Not provided
7	Berman et al (2019)	chatbots	RCT	78	USA	chronic pain	Not provided
8	Menga et al (2014)	chatbots	RCT	44	USA	Fibromyalgia	0.005 (severity of fibromyalgia)
9	O'moore et al (2018)	chatbots	RCT	69	Australia	osteoarthritis pain	Not provided
10	Gentili et al (2020)	Mobile apps	RCT	94	Germany	chronic low back pain	0.021(pain intensity)
11	Blödt et al (2018)	Mobile apps	RCT	221	Germany	menstrual pain	0.026 (pain intensity)
12	Schatz et al (2015)	Mobile apps	RCT	46	USA	chronic pain	0.1 (negative affect)
13	Sun et al (2017)	Mobile apps	RCT	46	China	cancer-related pain	<0.01 (pain intensity)
14	Calner et al (2017)	Mobile apps	RCT	109	USA	musculoskeletal pain	0.37 (intensity)
15	Chiauzzi et al (2010)	Mobile apps	RCT	199	USA	chronic pain	Not provided
16	Dowd et al (2015)	Mobile apps	RCT	124	Ireland	chronic pain	Not provided
17	Lin et al (2020)	Mobile apps	RCT	302	Germany	multimodal pain	0.01 (pain intensity); <0.01 (depression); 0.44 (anxiety);

							<0.01 (pain interference)
18	Ruehlmana et al (2012)	Mobile apps	RCT	305	USA	chronic pain	0.2 (pain intensity); 0.06 (depression); 0.15 (anxiety); 0.3 (pain interference)
19	Ström et al (2000)	Mobile apps	RCT	45	Sweden	recurrent headache	Not provided
20	Anderson et al (2004)	web-application	RCT	84	Netherlands	Cancer-related pain	Not provided

728

729

730 **Table 3.** Risk of bias, according to the revised risk-of-bias tool for randomised trials (RoB 2.0)

Author	Randomisation process	Deviations from the intended interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the reported result	Overall
Bossen et al (2013)	some concerns*	low risk	low risk	low risk	low risk	some concerns
Hedman-Lagerlöf, et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk
Krein et al (2013)	low risk	low risk	low risk	low risk	low risk	low risk
Rini et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Williams et al (2010)	low risk	low risk	low risk	low risk	low risk	low risk
Wilson et al	low risk	low risk	low risk	low risk	low risk	low risk

(2015)						
Raj et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Guillory et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Berman et al (2009)	low risk	low risk	low risk	low risk	low risk	low risk
Carpenter et al (2012)	low risk	low risk	low risk	low risk	low risk	low risk
Menga et al (2014)	low risk	low risk	low risk	low risk	low risk	low risk
O'moore et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk
Gentili et al (2020)	low risk	low risk	low risk	low risk	low risk	low risk
Minen et al (2019)	high risk**	low risk	low risk	low risk	low risk	high risk
Toelle et al (2019)	some concerns***	low risk	low risk	low risk	low risk	some concerns
Blödt et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk
Irvine et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Schatz et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Nebojsa et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Sun et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Guétin et al (2016)	low risk	low risk	low risk	low risk	low risk	low risk
Jamison et al	low risk	low risk	low risk	low risk	low risk	low risk

(2017)						
Jibb et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Lee et al (2017)	high risk**	low risk	low risk	low risk	low risk	high risk
Oldenmenger et al (2016)	low risk	low risk	low risk	low risk	low risk	low risk
Huber et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Calner et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk low risk
Chiauzzi et al (2010)	low risk	low risk	low risk	low risk	low risk	low risk
Davis et al (2013)	low risk	low risk	low risk	low risk	low risk	low risk
Dowd et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Lin et al (2020)	low risk	low risk	low risk	low risk	low risk	low risk
Nordin et al (2016)	low risk	low risk	low risk	low risk	low risk	low risk
Ruehlmana et al (2012)	low risk	low risk	low risk	low risk	low risk	low risk
Ström et al (2000)	low risk	low risk	low risk	low risk	low risk	low risk
Anderson et al (2004)	low risk	low risk	low risk	low risk	low risk	low risk
Lovell et al (2010)	low risk	low risk	low risk	low risk	low risk	low risk
Guétin et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk

Oldenmenger et al (2018)	high risk**	low risk	low risk	low risk	low risk	high risk
--------------------------	-------------	----------	----------	----------	----------	-----------

- 731 * Some concerns due to missing information regarding the allocation concealment.
- 732 ** High risk because of lack of randomisation.
- 733 *** Some concerns due to deviation from the protocol resulting in a 53:48 distribution of participants.

Figure 3. Representation of the PRISMA Flowchart




Figure 4. Mathematical model for data analysis

$$\begin{aligned}x_e^0 &\sim \mathcal{N}(m_e^0, s_e^{0^2}) \\x_e^1 &\sim \mathcal{N}(m_e^1, s_e^{1^2}) \\x_c^0 &\sim \mathcal{N}(m_c^0, s_c^{0^2}) \\x_c^1 &\sim \mathcal{N}(m_c^1, s_c^{1^2})\end{aligned}$$

Figure 6. Forest plot of pain intensity




Figure 7. Forrest plot of depression




Figure 8. Forest plot for anxiety




Figure 9. Forrest plot for pain interference




Figure 10. Forest plot of fatigue




Figure 11. Forrest plot of sleep




Figure 12 Subgroup analysis for pain intensity (web-application, mobile apps, chatbots)




Figure 13. Subgroup analysis for pain intensity (by pain type)




Figure 14a Subgroup analysis for pain intensity (by country)




Figure 14b Geographical spread of data collected for the systematic review




Figure 15. Sensitivity analysis without 3 BAME studies^{33,41,60}




Figure 16. Sensitivity analysis without 3 BAME studies^{33,41,60}

Number of studies = 4

Root MSE = 1.207

Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
slope	.5244641	.3811539	1.38	0.303	-1.115509	2.164437
bias	-2.348156	2.390633	-0.98	0.430	-12.63422	7.937908

Test of H0: no small-study effects

P = 0.430

(sub-grouped by digital applications)




Figure 17. (a) funnel plot for pain intensity; (b) egger's test for pain intensity.




Figure 18. (a) funnel plot for depression; (b) egger's test for depression.




Figure 19. (a) funnel plot for anxiety; (b) egger's test for anxiety.




Figure 20. Funnel plot for pain inferences




Figure 1. Chronic Pain Classification Tree (CPCT)




Figure 2. Acute Pain Classification Tree

